Several companies saw significant stock price movements in the premarket trading session, with notable declines for hims & hers health and chegg, amid earnings reports and new product launches by firms like eli lilly and keurig dr pepper.

Shares tumbled 22% after the company announced it would no longer sell compounded weight loss drugs.

Shares slipped 14% after fourth-quarter revenue fell short of expectations.

Shares rose 1% after launching higher dose vials of its weight loss drug Zepbound.

Shares plunged roughly 20% after reporting a net loss and suing Google over traffic issues.

Shares jumped nearly 3% after beating earnings and revenue expectations.